SCHEMBL16330167

SCHEMBL16330167

Cc1nc2c(cc1NCc1c(F)cc(F)cc1F)c(=O)c(C(=O)O)cn2[C@H](CO)C(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ METTL3 Q86U44 1/20 0.38
▸ CYP2C9 P11712 5/20 0.33
▸ LMNA P02545 3/20 0.33
▸ ATP6V1B2 P21281 1/20 0.33
▸ TBXA2R P21731 1/20 0.33
▸ EDNRA P25101 1/20 0.33
▸ TARBP2 Q15633 1/20 0.33
▸ JAK2 O60674 1/20 0.32
▸ JAK3 P52333 1/20 0.32
▸ PIM1 P11309 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ XBP1 P17861 1/20 0.32
▸ NFKB1 P19838 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ NFKB2 Q00653 1/20 0.32
▸ RELA Q04206 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1300337 0.89 METTL3 (0.41) METTL3CYP2C9LMNAATP6V1B2TBXA2R
SCHEMBL1300334 0.89 METTL3 (0.41) METTL3CYP2C9LMNAATP6V1B2TBXA2R
SCHEMBL1299822 0.89 LMNA (0.33) CYP2C9LMNAATP6V1B2TBXA2REDNRA
SCHEMBL1299817 0.89 LMNA (0.33) CYP2C9LMNAATP6V1B2TBXA2REDNRA
SCHEMBL1301047 0.88 METTL3 (0.37) METTL3CYP2C9LMNAATP6V1B2TBXA2R
SCHEMBL1301044 0.88 METTL3 (0.37) METTL3CYP2C9LMNAATP6V1B2TBXA2R
SCHEMBL12110689 0.85 LMNA (0.39) METTL3CYP2C9LMNAATP6V1B2TBXA2R
SCHEMBL12108308 0.84 METTL3 (0.41) METTL3CYP2C9LMNAATP6V1B2TBXA2R
SCHEMBL1300924 0.81 METTL3 (0.46) METTL3JAK2JAK3KDM4ECD38
SCHEMBL1300920 0.81 METTL3 (0.46) METTL3JAK2JAK3KDM4ECD38

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE AARDEA BIOSCIENCES, INC. (US) 2011-07-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE TYMP, SAMHD1, PNP METTL3 2709/4885CYP2C9 2322/4885LMNA 1312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback